Jump to main content
Jump to site search

Issue 7, 2012
Previous Article Next Article

De novo design, synthesis and pharmacological evaluation of new azaindole derivatives as dual inhibitors of Abl and Src kinases

Author affiliations

Abstract

A new fragment based drug design approach implemented in our MedChem-Decision platform led to the discovery of a new series of 2,5 disubstituted 7-azaindole derivatives as potent dual Abl and Src kinase inhibitors. Extensive structure–activity relationships and structure-based drug design studies guided the exploration of the specificity pocket within the active conformation of the ATP site of the two kinases. This led to (1) the identification of a new binding mode of the 7-azaindole core to the two kinases and (2) the synthesis and pharmacological evaluation of compounds that exhibit low nanomolar inhibition on both Abl and Src kinases as well as moderate activity on the Abl 315I mutant.

Graphical abstract: De novo design, synthesis and pharmacological evaluation of new azaindole derivatives as dual inhibitors of Abl and Src kinases

Back to tab navigation

Publication details

The article was received on 28 Jan 2012, accepted on 06 May 2012 and first published on 19 Jun 2012


Article type: Concise Article
DOI: 10.1039/C2MD20104F
Citation: Med. Chem. Commun., 2012,3, 788-800
  •   Request permissions

    De novo design, synthesis and pharmacological evaluation of new azaindole derivatives as dual inhibitors of Abl and Src kinases

    G. Chevé, C. Bories, B. Fauvel, F. Picot, A. Tible, B. Daydé-Cazals, O. Loget and A. Yasri, Med. Chem. Commun., 2012, 3, 788
    DOI: 10.1039/C2MD20104F

Search articles by author

Spotlight

Advertisements